The literature synthesized here signals a decisive shift away from amyloid-tau-centric models of Alzheimer's disease toward a more pluralistic framework centered on astrocytic reactivity, non-amyloid co-pathologies, and fluid biomarkers that capture disease heterogeneity. Hippocampal GFAP burden emerges as a pivotal construct, independently predicting cognitive decline across multiple domains while remaining dissociated from amyloid-β—instead tracking with neurofibrillary tangles, hippocampal sclerosis, and LATE-NC. This positions astrogliosis not as a mere bystander to classic AD pathology but as a distinct, mechanistically relevant axis linked to TDP-43 and tau-related neurodegeneration, measurable in post-mortem tissue from cohorts such as Rush ADRC and increasingly relevant to in vivo biomarker development.
A parallel trajectory is visible in CSF biomarker research, where MMP-10 and osteopontin are positioned as complementary analytes that refine diagnostic precision beyond core amyloid/tau measures. MMP-10 tracks cognitive decline and age at onset, while osteopontin correlates with amyloid-tau burden, and together they improve discrimination of AD from non-AD neurodegenerative conditions. This reflects a broader trend toward multi-marker panels that capture inflammatory, matrix-remodeling, and glial processes alongside canonical pathology—moving diagnostic and prognostic modeling toward systems that better reflect the mixed, multi-pathology reality of aging brains.
Down syndrome cohorts serve as a natural experiment illuminating this heterogeneity: despite near-universal amyloid pathology, only 29% show pure AD neuropathology, with substantial co-occurrence of cerebral amyloid angiopathy (84%), Lewy pathology (21%), hippocampal sclerosis (19%), and LATE-NC (17%)—the latter two occurring exclusively in demented individuals. This pattern underscores that dementia expression in Down syndrome, and by extension in the general aging population, depends on the accumulation of mixed co-pathologies rather than amyloid alone, and that some individuals harbor apparent resilience mechanisms that decouple pathology from clinical dementia despite high amyloid burden.
Collectively, these threads converge on a translational agenda: identifying fluid and imaging biomarkers (GFAP, MMP-10, osteopontin) that reflect specific pathological substrates—astrogliosis, TDP-43, tau, matrix remodeling—to enable stratified diagnosis, prognosis, and eventually targeted intervention in both sporadic AD and genetically vulnerable populations like those with Down syndrome. The mechanistic throughline is that cognitive decline in aging is polyetiological, demanding biomarker strategies and therapeutic targets that address glial reactivity and mixed co-pathology alongside amyloid and tau.